Moderna to Present at Upcoming Conferences in March 2022

Rhea-AI Summary

Moderna, Inc. (NASDAQ:MRNA) announced its schedule for three upcoming investor conferences in March 2022. The events include the Cowen 42nd Annual Health Care Conference on March 9 at 9:10 a.m. ET, the Barclays Global Healthcare Conference on March 15 at 1:30 p.m. ET, and the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 10:00 a.m. ET. Live webcasts will be available on Moderna's investor website, with replays accessible for 30 days post-event. Moderna continues to lead in mRNA therapeutics and has received recognition for its contributions to COVID-19 vaccine development.

CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:

• Cowen 42^nd Annual Health Care Conference on Wednesday, March 9^th at 9:10 a.m. ET
• Barclays Global Healthcare Conference on Tuesday, March 15^th at 1:30 p.m. ET
• Oppenheimer 32^nd Annual Healthcare Conference on Thursday, March 17^th at 10:00 a.m. ET

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/690983/Moderna-to-Present-at-Upcoming-Conferences-in-March-2022

FAQ

What conferences is MRNA participating in March 2022?

Moderna is participating in the Cowen 42nd Annual Health Care Conference on March 9, the Barclays Global Healthcare Conference on March 15, and the Oppenheimer 32nd Annual Healthcare Conference on March 17.

What time will Moderna's presentations take place at the conferences?

Moderna's presentations will be at 9:10 a.m. ET on March 9, 1:30 p.m. ET on March 15, and 10:00 a.m. ET on March 17.

Where can I find the webcasts for Moderna's conference presentations?

The live webcasts will be available under the 'Events and Presentations' section of Moderna's investor website.

How long will the webcasts from the conferences be available for replay?

The replays of the webcasts will be archived on Moderna's website for at least 30 days after each presentation.

What is Moderna known for in the biotechnology sector?

Moderna is known for pioneering messenger RNA (mRNA) therapeutics and vaccines, including its significant role in developing COVID-19 vaccines.